CLINICAL_TRIALS
trial_result
· 2025-04-04
Clinical Trial Update: Study of New Antiandrogenic Progestogen + Low-dose Estrogen for Moderate Acne Vulgaris [Phase 3]
Summary
Phase 3 study evaluating a new antiandrogenic progestin combined with low-dose estrogen for moderate acne vulgaris. The trial is not yet recruiting.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Snippet
Sponsor: Eurofarma Laboratorios S.A. | Conditions: Acne Vulgaris, Acne Vulgaris on the Face | Phase 3 | Status: NOT_YET_RECRUITING